Executive Reshuffle At Envigo
Executive Summary
Envigo has appointed Dr Adrian Hardy president and CEO, succeeding Brian Cass, who will become executive chair, whilst Andrew Baker will become chair emeritus. Cass joined the research services provider as managing director in 1998, and was appointed CEO in 2014. Hardy has been with the company since 2002, in which time he has held a number of roles of increasing responsibility, most recently serving as chief operating officer.
You may also be interested in...
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.
Pipeline Watch: Six Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.